Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen

Lignende værker

• Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction
  af: Rawstron, Andy C., et al.
  Udgivet: (2015)
• Assessment of Minimal Residual Disease in Myeloma and the Need for a Consensus Approach
  af: Rawstron, Andy C., et al.
  Udgivet: (2015)
• Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation
  af: Morgan, Gareth J., et al.
  Udgivet: (2011)
• Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results
  af: Morgan, Gareth J., et al.
  Udgivet: (2012)
• Minimal residual disease predicts superior survival in patients with multiple myeloma: a meta-analysis
  af: Munshi, Nikhil C., et al.
  Udgivet: (2017)